Combined radiotherapy and bleomycin in patients with inoperable head and neck cancer with unfavourable prognostic factors and severe symptoms

Minatel, Emilio; Gigante, Marco; Franchin, Giovanni; Gobitti, Carlo; Mascarin, Maurizio; Bujor, L.; Barzan, Luigi; Trovò, M.

doi:10.1016/s1368-8375(97)00073-0

Cited by 29 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Minatel et al treated 58 patients with 5000 cGy in 20 fractions with a 2-week break after the first 2500 cGy. 30 Patients received bleomycin during the first 3 weeks of treatment. Objective and symptom response rate were high at 69% and 81%; however, toxicity levels were on par with rates associated with curative intent therapy, with 43% of all patients experiencing grade 3 mucositis.…”

Section: Higher-dose (50-72 Gy) Regimensmentioning

confidence: 99%

Palliative Radiation Therapy for Head and Neck Cancers

Grewal

Jones

Lin

2019

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Patients with advanced head and neck cancers who are not eligible for curative treatment represent a challenging cohort of patients to manage given the complexity and severity of their presenting symptoms. Palliative radiation therapy, along with other systemic and surgical measures, has the potential to significantly improve the quality of life of such patients. There is little high-level evidence and a lack of consensus to direct the selection of an optimal palliative radiation regimen. An ideal palliative radiation regimen should alleviate symptoms secondary to the cancer with minimal treatment toxicity and side effects while improving a patient's quality of life. This review presents the treatment approaches, outcomes, and toxicities associated with different radiation regimens and proposes a multidisciplinary framework for the selection of an individualized treatment regimen for patients that centers around patient prognosis, goals of care, logistics of treatment, and the availability of other surgical and systemic therapies.

show abstract

Section: Higher-dose (50-72 Gy) Regimensmentioning

confidence: 99%

Palliative Radiation Therapy for Head and Neck Cancers

Grewal

Jones

Lin

2019

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

“…[240][241][242] Active and more commonly used single agents include cisplatin, carboplatin, paclitaxel, docetaxel, 5-FU, methotrexate, capecitabine, cetuximab (for non-nasopharyngeal cancer), and vinorelbine (for non-nasopharyngeal cancer). 239,[242][243][244][245][246][247][248][249][250][251][252][253][254][255][256][257][258][259][260] For the 2014 update, the panel revised the recommendations to category 2B for both ifosfamide and bleomycin because these agents are less commonly used; previously these agents had a category 2A recommendation.…”

Section: Metastatic Diseasementioning

confidence: 99%

Head and Neck Cancers, Version 2.2014

Pfister

Spencer

Brizel

et al. 2014

J Natl Compr Canc Netw

193

View full text Add to dashboard Cite

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers focuses on glottic laryngeal cancer, which is the most common type of laryngeal cancer and has an excellent cure rate. The lymphatic drainage of the glottis is sparse, and early stage primaries rarely spread to regional nodes. Because hoarseness is an early symptom, most glottic laryngeal cancer is early stage at diagnosis. Updates to these guidelines for 2014 include revisions to "Principles of Radiation Therapy" for each site and "Principles of Surgery," and the addition of a new section on "Principles of Dental Evaluation and Management."

show abstract

“…One of the earliest studies from Italy (Minatel et al.) evaluated the hypofractionated, split‐course palliative radiation combined with bleomycin 4 . They treated to 25 Gy in 10 fractions using 2.5 Gy daily, followed by a 2‐week break from treatment, and concluding with the second course of treatment (25 Gy in 10 fractions), to a total of 50 Gy.…”

Section: Discussionmentioning

confidence: 99%

“…More than 90% of patients completed their treatment, with 43% having grade III mucositis and 3% showing grade III dysphagia. A total of 81% of patients reported symptom control, whereas 69% of patients had excellent local control, which lasted for a median duration of 7 months 4 …”

Section: Discussionmentioning

confidence: 99%

“…One of the earliest studies from Italy (Minatel et al) evaluated the hypofractionated, split-course palliative radiation combined with bleomycin. 4 They treated to 25 Gy in 10 fractions using 2.5 Gy daily, followed by a 2-week break from treatment, and concluding with the In that study, they used the QUAD SHOT regimen and paclitaxel chemotherapy. 7 That study showed a statistically significant difference in the rate of complete response favoring the chemoradiation arm, both at the end of the treatment and at 6-month follow up, without any significant differences in toxicity between the treatment arms.…”

Section: Palliative Radiation Treatment Concurrently With Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Role of concurrent chemoradiotherapy and stereotactic body radiation treatment for palliation of previously untreated head and neck cancers

Thomas

Packianathan

Ahmed

et al. 2020

Precision Radiation Oncology

View full text Add to dashboard Cite

Palliative concurrent chemoradiotherapy has not been well evaluated for patients who are not a candidate for definitive treatment. Even though stereotactic radiotherapy has established a role in the re‐irradiation of recurrent head and neck tumors, its role is not established as a possible primary treatment modality for patients who are not eligible for curative treatment. This article reviews the available literature on the role of chemoradiotherapy and stereotactic radiation for palliation of previously untreated head and neck cancers.

show abstract

Combined radiotherapy and bleomycin in patients with inoperable head and neck cancer with unfavourable prognostic factors and severe symptoms

Cited by 29 publications

References 12 publications

Palliative Radiation Therapy for Head and Neck Cancers

Palliative Radiation Therapy for Head and Neck Cancers

Head and Neck Cancers, Version 2.2014

Role of concurrent chemoradiotherapy and stereotactic body radiation treatment for palliation of previously untreated head and neck cancers

Contact Info

Product

Resources

About